BioCentury
ARTICLE | Top Story

ReoPro shows no benefit in ACS

August 28, 2000 7:00 AM UTC

In the international 7,800-patient Phase III GUSTO IV-ACS trial conducted by Johnson & Johnson (JNJ) and partner Eli Lilly (LLY), the combined end point of death or myocardial infarction at 30 days wa...